(Q74360823)
Statements
Phase I trial of the colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-hour continuous intravenous infusion (English)
Eder JP Jr
Supko JG
Lynch T
Bryant M
Vosburgh E
Shulman LN
Xu G
1 February 1998